Amiodarone-induced pulmonary toxicity

Pharmacotherapy

Volumn 19, Issue 12, 1999, Pages 1463-1466

  Kanji, Zahra ^a,b,c   Sunderji, Rubina ^a,b   Gin, Kenneth ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

^c LIONS GATE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; CARDARONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CASE REPORT; HUMAN; LUNG FUNCTION TEST; LUNG TOXICITY; MALE; MORTALITY; PROGNOSIS; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

EID: 0032737085     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.19.18.1463.30890     Document Type: Article

References (19)

1. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. JAMA 1993;270:1589-95.
2. Podrid PJ. Amiodarone: revaluation of an old drug. Ann Intern Med 1995;122:689-700.
3. Doval HC, Nul DR, Grancelli HO, Perrone SV, Bortman GR, Curiel R. Randomized trial of low dose amiodarone in severe congestive heart failure. Lancet 1994;344:493-8.
4. Singh SN, Fletcher RD, Fisher SG, et al. Amiodarone in patients with congestive heart failure and asymptomatic ventricular arrhythmia. N Engl J Med 1995;333:77-82.
5. Cairns JA, Connolly SJ, Roberts R, Gent M. Randomized trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarizations: CAM1AT. Lancet 1997;349:675-82.
6. Julian DG, Camm AJ, Frangin G, et al. Randomized trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent myocardial infarction: EM1AT. Lancet 1997;349:667-74.
7. Pitcher WD. Southwestern internal medicine conference: amiodarone pulmonary toxicity. Am J Med Sci 1992;393:206-12.
8. Fraire AE, Guntipalli KK, Greenberg SD, Cartwright J, Chasen MH. Amiodarone pulmonary toxicity: a multidisciplinary review of current status. South Med J 1993;86:67-77.
9. Kudenchuk PJ, Pierson DJ, Greene HL, et al. Prospective evaluation of amiodarone pulmonary toxicity. Chest 1984;86:541-8.
10. Hilleman D, Miller MA, Parker R, et al. Optimal management of amiodarone therapy: efficacy and side effects. Pharmacotherapy 1998:18(6 pt 2):138S-45.
11. Zitnik RJ. Drug-induced lung disease: antiarrhylhmic agents. J Respir Dis 1996;17:254-70.
12. Valle JM, Alvarez D, Antunez J, Valdes L. Bronchiolitis obliterans organizing pneumonia secondary to amiodarone: a rare etiology. Eur Respir J 1995;8:470-1.
13. Arnon R, Raz I, Chajek-Shaul T, et al. Amiodarone pulmonary toxicity presenting as a solitary lung mass. Chest 1998;93:425.
14. Piccione W, Faber LP, Rosenberg MS. Amiodarone-induced pulmonary mass. Ann Thorac Surg 1989;47:18.
15. Dusman RE, Stanton MS, Miles WM, et al. Clinical features of amiodarone-induced pulmonary toxicity. Circulation 1990;82:51-9.
16. Martin WJ, Rosenow EC III. Amiodarone pulmonary toxtcity: Recognition and pathogenesis (part I). Chest 1988;93: 1067-75.
17. Zaher C, Hamer A, Peter T, et al. Low dose steroid therapy for prophylaxis of amiodarone-induced pulmonary infiltrates. N Engl J Med 1983;308:779.
18. Coudert B, Bailly F, Lombard JN, et al. Amiodarone pneumonitis. Bronchoalveolar lavage findings in 15 patients and review of the literature. Chest 1992;102:1005.
19. Singh BN. Amiodarone: the expanding antiarrhythmic role and how to follow a patient on chronic therapy. Clin Cardiol 1997;20:608-18.